![Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response | Science Advances Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response | Science Advances](https://www.science.org/cms/10.1126/sciadv.abq8276/asset/56cd15ef-f5ac-4458-9cec-7c8da0a51743/assets/images/large/sciadv.abq8276-f4.jpg)
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response | Science Advances
![Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen: Molecular Therapy Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen: Molecular Therapy](https://www.cell.com/cms/attachment/44330896-4245-4dcf-9bb4-ac9c48dc327b/gr1_lrg.jpg)
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen: Molecular Therapy
![Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy](https://www.cell.com/cms/asset/7560a09b-9f15-49d3-8070-5067ba6d4ad4/fx1.jpg)
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy
![Frontiers | Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model Frontiers | Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model](https://www.frontiersin.org/files/Articles/641447/fimmu-12-641447-HTML/image_m/fimmu-12-641447-g001.jpg)